EXONDYS 51 Drug Patent Profile

Which patents cover Exondys 51, and when can generic versions of Exondys 51 launch?

Exondys 51 is a drug marketed by Sarepta Theraps Inc and is included in one NDA. There are five patents protecting this drug.

This drug has one hundred and twenty-nine patent family members in twenty-three countries.

The generic ingredient in EXONDYS 51 is eteplirsen. One supplier is listed for this compound. Additional details are available on the eteplirsen profile page.

DrugPatentWatch^® Generic Entry Outlook for Exondys 51

Exondys 51 was eligible for patent challenges on September 19, 2020.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 2, 2029. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for EXONDYS 51

International Patents:	129
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EXONDYS 51
What excipients (inactive ingredients) are in EXONDYS 51?	EXONDYS 51 excipients list
DailyMed Link:	EXONDYS 51 at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for EXONDYS 51

Constraining patent/regulatory exclusivity:

RE47769

NDA:

206488

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for EXONDYS 51

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sarepta Therapeutics, Inc.	Phase 3
Sarepta Therapeutics	Phase 3
Catabasis Pharmaceuticals	Phase 1/Phase 2

See all EXONDYS 51 clinical trials

Pharmacology for EXONDYS 51

Drug Class

Antisense Oligonucleotide

US Patents and Regulatory Information for EXONDYS 51

EXONDYS 51 is protected by seven US patents.

This potential generic entry date is based on patent RE47769.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-001	Sep 19, 2016		RX	Yes	Yes	9,506,058
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-001	Sep 19, 2016		RX	Yes	Yes	RE47769		Y
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-002	Sep 19, 2016		RX	Yes	Yes	10,337,003

Expired US Patents for EXONDYS 51

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-001	Sep 19, 2016	9,018,368
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-001	Sep 19, 2016	RE47751
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-002	Sep 19, 2016	10,781,451

EU/EMA Drug Approvals for EXONDYS 51

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AVI Biopharma International Ltd	Exondys	eteplirsen	EMEA/H/C/004355Treatment of Duchenne muscular dystrophy.	Refused	no	no	yes		2018-12-06

International Patents for EXONDYS 51

See the table below for patents covering EXONDYS 51 around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2014233456
Australia	2019203505
Australia	2020260492

Last updated: May 24, 2026

EXONDYS 51 (golodirsen) market dynamics and financial trajectory

Executive summary: EXONDYS 51 (golodirsen) is a specialty, single-indication Duchenne muscular dystrophy (DMD) therapy with narrow eligibility tied to the DMD gene exon 51-skipping biomarker. Its market growth has been constrained by small treatable populations, payer resistance to high price-per-responder frameworks, and competitive pressure from other exon-skipping approaches. Financial trajectory is dominated by (1) adoption within the exon 51 eligible segment, (2) net price and rebates, (3) manufacturing reliability and supply continuity, and (4) life-cycle and pipeline displacement risk from next-generation therapies targeting similar mutation subsets.

What is EXONDYS 51’s commercial profile (sales drivers, payer structure, patient segment)?

Direct answer: EXONDYS 51 is priced and reimbursed as a high-cost, low-prevalence gene-exon skipping therapy. Demand is driven by mutation prevalence for DMD exon 51 and by clinician adoption of exon-skipping biomarker testing, with payer coverage often requiring evidence of diagnosis confirmation and eligibility.

Which patients buy-side and prescriber-side dynamics shape uptake?

• Eligibility funnel: EXONDYS 51 use is tied to confirmed DMD mutations amenable to exon 51 skipping (commonly described as “skipping mutation confirmed by genetic testing”), plus clinical criteria typical of DMD standards of care.
• Diagnosing infrastructure: Uptake is dependent on access to genetic testing for DMD mutation stratification, with downstream effects on referral patterns to DMD specialty centers.
• Clinical differentiation: As an antisense oligonucleotide (ASO) delivered by IV infusion, adoption depends on comparative real-world experience versus alternative exon-skipping products and supportive care benchmarks.

How do payer policies typically constrain revenue?

• Prior authorization and response criteria: Coverage is usually tied to documentation of mutation eligibility and baseline/serial biomarkers (in practice, approaches vary by payer contract).
• Rebates and net-to-gross compression: High list price products with constrained populations commonly experience meaningful rebates that reduce realized net pricing versus headline acquisition cost.
• Budget impact management: Formularies and specialty pharmacy contracting can slow initiation in non-specialty integrated systems.

What is the competitive set for EXONDYS 51 from a market standpoint?

• Exon-skipping competitors (same therapeutic goal class): Other DMD exon-skipping ASOs (each linked to specific exons) compete for a share of the treated exon-specific segment rather than for a broader DMD population.
• Non-ASO DMD modalities: Newer approaches in DMD that target different mechanisms can indirectly cap addressable share by shifting prescriber preferences and payer willingness to fund.

How big is the treatable market for exon 51 DMD and what does that mean for EXONDYS 51 revenue ceiling?

Direct answer: EXONDYS 51’s revenue ceiling is bounded by the proportion of DMD patients with mutations appropriate for exon 51 skipping and by the rate at which eligible patients reach diagnosis, testing, and treatment initiation.

Key market-sizing variables

• Mutation frequency: The share of DMD patients with exon 51 amenable mutations.
• Treatment initiation rate: The fraction of genetically eligible patients who actually start therapy (affected by access, payer approval timelines, infusion infrastructure).
• Discontinuation risk: Real-world discontinuation can occur due to lack of perceived benefit, adverse events, access barriers, or payer reconsideration.
• Geographic coverage: Revenue is sensitive to country-by-country reimbursement structures, even when regulatory approvals exist.

What drives year-to-year revenue changes?

• New patient starts: Annual growth depends more on incident starts than on “patient count retention,” since IV ASOs are chronic and patients can remain on therapy for years.
• Net pricing: Net revenue can rise or fall even with stable patient counts due to changes in rebate structures, tender outcomes, or payer contract renegotiations.
• Supply and continuity: Any delivery disruptions directly impact patient retention and initiation and can create revenue volatility.

When do market dynamics turn negative for EXONDYS 51 (patent and exclusivity endgame versus competitive substitution)?

Direct answer: Risk peaks when exclusivity and patent-protected market advantages erode, when competitive ASOs consolidate share in overlapping mutation subsets, and when payer coverage tightens based on comparative value assessments.

What time horizons matter for EXONDYS 51’s market position?

• Regulatory and IP life-cycle: Net revenue exposure depends on (1) protection of the specific ASO sequence/dosing regimen and formulation/manufacturing, and (2) any method-of-use or clinical endpoint-related patents.
• Competitive substitution: Even before generic/BS entry is possible, prescribers may shift to products with differentiated administration profiles, perceived efficacy signals, or improved payer coverage.

How do competitive dynamics show up financially?

• Patient mix shift: If competing exon-skipping drugs expand within the same DMD center networks, EXONDYS 51 can face slower new-start growth.
• Net-to-gross pressure: Competitive pricing pressure plus payer leverage can reduce realized net revenue per patient.
• Contracting leverage: Larger pharmacy benefit managers or integrated systems can drive stronger rebate demands over time.

What is the EXONDYS 51 financial trajectory (sales trend, growth rate, drivers)?

Direct answer: EXONDYS 51 has historically remained a niche blockbuster rather than a mass-market drug. Its financial trajectory is typically characterized by modest total sales volume, with performance influenced more by patient starts and net pricing than by broad market penetration.

Financial trajectory map (how to interpret the numbers)

• Early commercialization phase: Adoption is constrained by genetic testing availability and payor contracting. Revenue ramps primarily through incremental starts in DMD specialty centers.
• Mature phase: Growth, if present, tends to be limited to new patient starts, minor expansion into additional payers/centers, and incremental retention.
• Value reassessment phase: If payers tighten evidence thresholds or expand comparative effectiveness scrutiny, net pricing and initiation speed can both soften.

Metrics that matter to equity and licensing decisions

• Net revenue per treated patient (after rebates)
• Total treated patient count (or proxy measures)
• Share of new DMD starts by exon subset in large regional networks
• Seasonality and dosing schedule compliance impacting infusion continuity and supply usage

How does EXONDYS 51 pricing and net revenue dynamics drive profitability?

Direct answer: Profitability is sensitive to (1) net price compression via rebates, (2) manufacturing scale and yield in ASO oligonucleotide production, and (3) patient volume that spreads high fixed development and commercial costs.

Cost structure and margin drivers

• Manufacturing and quality costs: ASO production has quality and release testing intensity. Yield and batch release performance affect unit costs.
• Commercial support and specialty distribution: High-touch payer operations, prior authorization support, and infusion ecosystem servicing influence selling expenses.
• Pipeline reinvestment: Company spending priorities shift based on expected persistence of the therapy’s commercial advantage.

What generic or biosimilar risks exist for EXONDYS 51 and how do they affect financial outlook?

Direct answer: For small-molecule generics the risk profile is straightforward, but EXONDYS 51 is an oligonucleotide therapy. The principal competitive risk is not classic small-molecule generic substitution; instead it is the ability of competitors to develop an equivalent oligonucleotide with comparable sequence identity and clinical performance, along with successful regulatory and IP navigation.

Commercial impact pathways from competitive entry

• Volume erosion: Even partial substitution can reduce new starts and later shift patient persistence.
• Price pressure: Payers often use competitive bids to drive down realized net pricing.
• Contract renegotiation cycles: Contracts can reprice at renewal after a competitor becomes available.

How does EXONDYS 51 compare with other DMD exon-skipping therapies in market behavior?

Direct answer: EXONDYS 51’s market behavior tracks the smaller exon-51 eligible population and payer willingness to fund that segment. Competitors with larger exon target populations or more favorable contracting can outgrow it, even if all products show similar payer resistance patterns.

Comparison dimensions that affect commercial outcomes

• Mutation subset size
• Per-patient annual cost and rebate intensity
• Perceived efficacy in biomarkers and clinical practice
• Payer coverage ease and center network adoption
• Infusion scheduling practicality and supply stability

What regulatory milestones and FDA status factors affect adoption economics?

Direct answer: FDA labeling specificity tied to the exon skipping indication shapes clinical decision-making, which in turn drives payer acceptance and patient starts.

Coverage and label interpretation

• Payers tend to align authorization criteria tightly with labeled eligibility and commonly require evidence of mutation status.
• Any labeling updates that expand eligible populations typically accelerate commercial uptake; labeling restrictions can do the opposite.

What patent estate issues are most relevant to market stability for EXONDYS 51?

Direct answer: Market stability depends on how comprehensively the patent estate covers the oligonucleotide composition, dosing regimen, formulation, and manufacturing. Weakness in any of these dimensions increases competitive entry risk and can depress valuation even before the first credible competitor launches.

How to map patent estate to financial exposure

• Composition-of-matter scope: Limits direct sequence or structural design-around.
• Formulation/manufacturing patents: Control “equivalent” production routes and release specifications.
• Method-of-use and clinical endpoint patents: Often determine litigation leverage and payer negotiation posture when evidence standards are contested.

Key Takeaways

• EXONDYS 51 demand is driven by the narrow exon 51 DMD mutation segment and by genetic testing access that determines who reaches treatment eligibility.
• Revenue is constrained more by eligible population size and payer contracting than by broader DMD market penetration.
• Financial performance depends on net pricing after rebates, incident patient starts, and therapy continuity.
• Competitive and lifecycle risks (including exon-skipping substitutes and eventual oligonucleotide equivalence challenges) drive downside to net revenue, patient growth, and realized price.

FAQs

1. How do payer prior authorization requirements typically affect EXONDYS 51 initiation timelines?
2. What are the main indicators of declining uptake for exon-skipping drugs in DMD specialty centers?
3. How does genetic testing capacity influence commercialization speed for EXONDYS 51?
4. What contract renewal dynamics drive net pricing changes for high-cost DMD therapies?
5. How do oligonucleotide-specific entry risks differ from classic generic small-molecule risk for EXONDYS 51?

References

1. Bloomberg Law (Orange Book and patent litigation datasets).
2. U.S. Food and Drug Administration (FDA) Drug approvals and labeling for EXONDYS 51 (golodirsen).
3. FDA Orange Book database (golodirsen listings and associated patents).